PDCD1 and neoplasm: For example, a T-cell inflamed signature based on IFN-γ genes was associated with response to anti-PD-1 therapy in multiple tumor types [35], and an algorithmic approach which combines gene expression profiling with tumor mutational burden (TMB) and PD-L1 IHC improves prediction of response to ICIs in melanoma [37].